Supplementary Table S1 from Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial.
Year: 2025
Type: supplementary-materials
Abstract: Table S1: Best overall response (RECIST v1.1) of leiomyosarcoma patients on the DAPPER study
Authors: Abdulazeez Salawu, Ben X. Wang, Ming Han, Caryn Geady, Alya Heirali, Hal K. Berman, Thomas D. Pfister, Alberto Hernando-Calvo, Esmail Mutahar Al-Ezzi, Lee-Anne Stayner, Abha A. Gupta, Olubukola Ayodele, Bernard Lam, Aaron R. Hansen, Anna Spreafico, Philippe L. Bedard, Marcus O. Butler, Lisa Avery, Bryan Coburn, Benjamin Haibe-Kains, Lillian L. Siu, Albiruni R. Abdul Razak
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4416630241
Cites:
Cited by:
Related to: